Abstract
The management of metastatic progressive radioiodine-resistant differentiated thyroid cancer has remained a challenge for clinicians. The availability of tyrosine kinase inhibitors (TKIs) within the last decade has expanded the treatment options, but these come with significant adverse effects that may curtail their use.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
